Bellevue Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $612K | Sell |
4,646
-1,698,658
| -100% | -$225M | 0.01% | 105 |
|
|
2025
Q4 | $242M | Sell |
1,703,304
-59,801
| -3% | -$8.66M | 4.58% | 5 |
|
|
2025
Q3 | $248M | Sell |
1,763,105
-56,895
| -3% | -$7.71M | 5.14% | 4 |
|
|
2025
Q2 | $229M | Hold |
1,820,000
| – | – | 5.04% | 3 |
|
|
2025
Q1 | $201M | Hold |
1,820,000
| – | – | 4.51% | 7 |
|
|
2024
Q4 | $248M | Sell |
1,820,000
-43,800
| -2% | -$5.42M | 4.78% | 3 |
|
|
2024
Q3 | $215M | Sell |
1,863,800
-34,840
| -2% | -$4.78M | 3.48% | 7 |
|
|
2024
Q2 | $261M | Sell |
1,898,640
-157,234
| -8% | -$21.6M | 4.25% | 4 |
|
|
2024
Q1 | $284M | Sell |
2,055,874
-374,626
| -15% | -$51.2M | 4.32% | 3 |
|
|
2023
Q4 | $320M | Sell |
2,430,500
-153,050
| -6% | -$17.6M | 4.9% | 3 |
|
|
2023
Q3 | $291M | Sell |
2,583,550
-29,250
| -1% | -$3.08M | 4.68% | 4 |
|
|
2023
Q2 | $246M | Sell |
2,612,800
-500
| -0% | -$48.9K | 3.51% | 5 |
|
|
2023
Q1 | $265M | Sell |
2,613,300
-159,994
| -6% | -$16.6M | 3.84% | 4 |
|
|
2022
Q4 | $331M | Sell |
2,773,294
-81,852
| -3% | -$9.59M | 4.4% | 3 |
|
|
2022
Q3 | $303M | Buy |
2,855,146
+10,841
| +0.4% | +$1.1M | 4.35% | 4 |
|
|
2022
Q2 | $277M | Sell |
2,844,305
-179,146
| -6% | -$16.5M | 3.92% | 4 |
|
|
2022
Q1 | $283M | Sell |
3,023,451
-157,100
| -5% | -$13.3M | 3.29% | 4 |
|
|
2021
Q4 | $271M | Buy |
3,180,551
+176,500
| +6% | +$16.2M | 2.79% | 5 |
|
|
2021
Q3 | $288M | Sell |
3,004,051
-13,700
| -0.5% | -$1.29M | 2.92% | 5 |
|
|
2021
Q2 | $294M | Sell |
3,017,751
-256,800
| -8% | -$24.6M | 2.87% | 4 |
|
|
2021
Q1 | $318M | Sell |
3,274,551
-122,100
| -4% | -$12.8M | 3.37% | 3 |
|
|
2020
Q4 | $326M | Buy |
3,396,651
+99,200
| +3% | +$9.58M | 3.73% | 2 |
|
|
2020
Q3 | $317M | Buy |
3,297,451
+86,551
| +3% | +$10M | 4.38% | 2 |
|
|
2020
Q2 | $392M | Sell |
3,210,900
-48,574
| -1% | -$5.37M | 5.54% | 2 |
|
|
2020
Q1 | $282M | Sell |
3,259,474
-58,900
| -2% | -$5.76M | 5.47% | 3 |
|
|
2019
Q4 | $357M | Buy |
3,318,374
+19,900
| +0.6% | +$2.08M | 5.66% | 2 |
|
|
2019
Q3 | $297M | Sell |
3,298,474
-247,970
| -7% | -$23.2M | 5.53% | 2 |
|
|
2019
Q2 | $299M | Buy |
3,546,444
+3,526,244
| +17,457% | +$290M | 5.11% | 3 |
|
|
2019
Q1 | $1.78M | Sell |
20,200
-19,850
| -50% | -$1.66M | 0.1% | 112 |
|
|
2018
Q4 | $2.86M | Sell |
40,050
-1,500
| -4% | -$144K | 0.19% | 92 |
|
|
2018
Q3 | $5.11M | Sell |
41,550
-2,000
| -5% | -$227K | 0.32% | 71 |
|
|
2018
Q2 | $4.28M | Sell |
43,550
-10,100
| -19% | -$904K | 0.36% | 59 |
|
|
2018
Q1 | $4.45M | Sell |
53,650
-850
| -2% | -$71.8K | 0.44% | 55 |
|
|
2017
Q4 | $4.23M | Sell |
54,500
-1,500
| -3% | -$102K | 0.44% | 52 |
|
|
2017
Q3 | $3.43M | Buy |
56,000
+9,000
| +19% | +$475K | 0.36% | 63 |
|
|
2017
Q2 | $2.16M | Sell |
47,000
-21,000
| -31% | -$1.02M | 0.26% | 79 |
|
|
2017
Q1 | $2.94M | Sell |
68,000
-7,000
| -9% | -$300K | 0.39% | 65 |
|
|
2016
Q4 | $2.9M | Buy |
75,000
+17,000
| +29% | +$770K | 0.59% | 48 |
|
|
2016
Q3 | $2.94M | Hold |
58,000
| – | – | 0.53% | 55 |
|
|
2016
Q2 | $2.64M | Sell |
58,000
-7,000
| -11% | -$322K | 0.5% | 65 |
|
|
2016
Q1 | $2.57M | Buy |
+65,000
| New | +$2.58M | 0.47% | 69 |
|
Other funds holding NBIX
VPM
VCM
Bellevue Group's NBIX Position: Q1 2026 in Review
Bellevue Group reduced its Neurocrine Biosciences (NBIX) stake by 100% in Q1 2026, selling an estimated $225M and leaving 4,646 shares worth $612K. The position accounts for 0.01% of the portfolio, ranked #105.
Bellevue Group first reported a position in NBIX in Q1 2016 and has held it in 41 quarters since. The position peaked at $392M in Q2 2020. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Bellevue Group held 4,646 shares of Neurocrine Biosciences worth $612K as of Q1 2026.
- Bellevue Group sold 1,698,658 Neurocrine Biosciences shares in Q1 2026, an estimated $225M.
- Neurocrine Biosciences made up 0.01% of Bellevue Group's portfolio in Q1 2026, its #105 holding.
- Bellevue Group first reported a position in Neurocrine Biosciences in Q1 2016 and has held it in 41 quarters since.
- Bellevue Group's Neurocrine Biosciences position peaked at $392M in Q2 2020.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.